Author details

Full Name

Charles D James

Affiliation

ORCID

Career Start Year

1988

Papers

243

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37444539	WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas.	Cancers (Basel)	2023
37847564	Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.	J Clin Invest	2023
37196077	Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production.		2023
36382088	SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression.	Cancer Res Commun	2022
36428586	Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts.	Cancers (Basel)	2022
36410047	Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.	Journal of Medicinal Chemistry	2022
34647022	Glioblastoma as an age-related neurological disorder in adults.	Neurooncol Adv	2021
33855339	De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.	Brain	2021
33692132	A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.	Sci Transl Med	2021
33627401	Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity.	Proceedings of the National Academy of Sciences of the United States of America	2021
32827353	Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges.	Pediatr Blood Cancer	2021
33028660	Heparan Sulfate Synthesized by <i>Ext1</i> Regulates Receptor Tyrosine Kinase Signaling and Promotes Resistance to EGFR Inhibitors in GBM.	Mol Cancer Res	2021
33272983	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.	Clin Cancer Res	2021
32102285	Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and Implications for Clinical Application.	Cancers (Basel)	2020
31462429	SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.	Cancer Res	2019
30266764	Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.	Clin Cancer Res	2019
30415456	Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.	J Neurooncol	2019
30651332	Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.	Journal of Neuroscience	2019
30654687	MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.	Autophagy	2019
30926789	Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.	Cell Death and Disease	2019
31005631	Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas.	Neoplasia	2019
31201162	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.	Cancer Res	2019
31105875	Correction: Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.	Oncotarget	2019
29500275	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.	Clin Cancer Res	2018
29042487	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.	Mol Cancer Res	2018
30174560	Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging.	Contrast Media Mol Imaging	2018
29927689	Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.	Epigenetics	2018
30151703	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.	J Neurooncol	2018
30084265	An overview of meningiomas.	Future Oncology	2018
29660019	Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.	Neuro Oncol	2018
28137267	Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy.	Mol Cancer	2017
28464039	Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.	PLoS ONE	2017
28672195	Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.	Translational Oncology	2017
28416018	Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.	Acta Neuropathol Commun	2017
28373576	Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2017
28751450	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.	Clin Cancer Res	2017
28321824	Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.		2017
28564604	Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.	Cell Rep	2017
28355568	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.	Cell Rep	2017
29232556	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma.	Cancer Cell	2017
28278424	Therapeutic Potential for Bone Morphogenetic Protein 4 in Human Malignant Glioma.	Neoplasia	2017
27611946	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.	Oncotarget	2017
28263307	Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.	Nat Med	2017
27848137	Combined BRAF<sup>V600E</sup> and MEK blockade for BRAF<sup>V600E</sup>-mutant gliomas.	J Neurooncol	2017
27713119	Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.	Oncotarget	2016
27370397	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.	Neuro Oncol	2016
27364770	MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.	Mol Cancer Res	2016
26782702	Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.	J Neurooncol	2016
27217440	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.	Clin Cancer Res	2016
27070703	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.	Cancer Cell	2016